Work

Switch of the mutation type of the NPM1 gene in acute myeloid leukemia (AML): relapse or secondary AML?

Year: 2014
Type: article
Abstract: Mutations in exon 12 of the nucleophosmin ( NPM1 ) gene have been described as primary leukemogenic event in up to 35% of adult acute myelogenous leukemia (AML) cases, mainly those with normal karyotype. 1 This type of AML is listed as provisional entity in the World Health Organization classification of tumors of the hematopoietic and lymphoid tissues 2008. NPM1 mutation status has improved risk stratification and therapy choice of the AML intermediate-risk group with normal karyotype, as NPM1- mutated cases without fms-related tyrosine kinase 3 ( FLT3 ) gene internal tandem duplications have a favorable outcome and no need for bone marrow transplantation first line. 2 Furthermore, mutations in other genes—for example, isocitrate dehydrogenase ( IDH1 and IDH2 genes)—seem to influence prognosis as patients with both NPM1 and IDH mutations show improved overall 3-year survival, whereas NPM1 -positive cases without IDH mutations have a much less favorable outcome. 3
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: gold
Estimated APC paid: $5,290
OpenAlex ID: W2018564687
FWCI: 0.356
Cites: 11
Cited by: 12
Related to: 9